Hearing · MYO6 c.2416+5G>A
Logbook (NL)
NL EN

Open notebook · last updated 23 September 2026

I have been hard of hearing since I was ten or eleven. In 2020 it got a name. Now I know which letter it is.

My hearing loss is hereditary. It has run in the family for at least four generations. The cause is one wrong letter in one gene: MYO6. That gene is the recipe for a small motor protein that keeps the tiny sensory hairs in my inner ear in place. If that motor doesn't work properly, those hairs break down, the high tones first. This is what I know, what I'm trying, and where it gets stuck.

Translated from the Dutch original. The 3D explainers are in English; the logbook, the knowledge base and the linked background pages are in Dutch.

4generations affected in the family
~10–12years old when it started, after an ear infection
14 yearsof my own measurements, 11 audiograms
1 letterdifference between the two copies of the gene

See it in 3D

five interactive 3D animations · with voice-over, always subtitled

From my chromosomes to a mini-ear in a culture dish. Pause to look around for yourself; at the end of each part there is something to try yourself.

What it actually is

What I am losing is not volume, it is clarity

Say "hard of hearing" and almost everyone thinks of quieter. In my case that is the least interesting half of the story.

I have fourteen years of measurements. If you look at how loud sound has to be before I hear it, hardly anything has changed in the speech range: the point at which I pick up half of the speech sounds moved by five decibels in fourteen years. That is not much.

But play the sound at the same loudness and count how many words I understand correctly, and it drops fast. In 2012 that was 94 out of 100. In 2019, 85. In 2026, 70. Same loudness, fewer and fewer words right. And the rate of decline nearly doubled, from 1.3 to 2.2 percentage points per year.

left ear, unaided, everything presented at the same level of 100 dB

Percentage of speech sounds understood correctly at the same presentation level (100 dB), left ear, from three clinical speech audiograms. The 24-percentage-point difference between 2012 and 2026 is statistically robust (p ≈ 0.008). The two 2012 measurements come from different centres, six weeks apart, and agree within two percentage points.

That is also how it feels. Speaking louder doesn't help, because the problem isn't that it is too quiet; it is that the difference between words like bed, bet and beg gets less and less clear. Hearing aids have improved a lot over the same period and largely make up for the decline, but that will run out at some point.

Why that fits this gene. Myosin VI is found, among other places, where the hair cell passes its signal on to the auditory nerve. If things go wrong there, this is exactly the picture you would expect: the threshold barely moves, understanding collapses.

And this is where in the sound it sits

Not everything is equally gone. One part still works, and that happens to be exactly the part that matters.

low tones125 – 500 HzModerately affected, and nearly stable for fourteen years.
speech range500 Hz – 2 kHzThis is where speech lives. It is the part that is still there, and so the part a treatment has to save.
high tonesabove ~3 kHzNothing left, not even at maximum volume. Nothing to save here.

What happens in the cell

From one wrong letter to a sensory hair that falls over

Four steps. You don't need any biology, just the order.

  1. 1 · THE RECIPE

    The MYO6 gene is the recipe for myosin VI, a small motor protein in the hair cell.

  2. 2 · THE ERROR

    In one place there is a wrong letter, right at the seam between two pieces of the recipe.

  3. 3 · THE WORKING COPY

    Because of it, a piece is skipped when the working copy is made, and the rest no longer reads correctly.

  4. 4 · THE CELL

    The hair cell has only half of its motor. Presumably the base of the sensory hairs slowly wears down as a result, and the signal drops out, high tones first.

Step 4 is exactly the shape of the hearing loss above: the high tones go first.

There are four short animations that show this step by step, all interactive and in 3D, plus an extra one on growing a mini-ear. They have a voice-over you can switch off; everything is also shown as subtitles.

The 23 chromosome pairs, with pair 6 in orange▶ Watch in 3D

From chromosome to protein

± 2:10 · Interactive, in 3D: from a cell via 23 chromosome pairs and the double helix to the MYO6 gene of 170,299 letters, how it is cut and spliced, and how myosin VI is made from it. With a zoom slider from cell to protein.

The letters around the seam of piece 23, with the fifth letter changed from G to A▶ Watch in 3D

What my variant does

± 2:25 · Interactive, in 3D: the single letter at the seam of piece 23, the skipped piece, the stop signal that immediately follows as a result, and the two possible outcomes. At the end you can explore the reading frame yourself, with the real letters from the gene.

The hair bundle of a hair cell in 3D▶ Watch in 3D

What myosin VI does in the hair cell

± 2:30 · Interactive, in 3D: from my ear to the cochlea, to a single hair cell. Pause to look around for yourself, and at the end pick a pitch to see which spot in the cochlea still responds.

Prefer a regular video? (2:26, in Dutch)

Two copies of the gene filling a dosage meter▶ Watch in 3D

The dosage paradox

± 2:35 · Interactive, in 3D: why half a dose of MYO6 does cause disease, while others with the same half hear normally. At the end, a dosage slider lets you see what is known for each amount, and what is not.

Prefer a regular video? (2:08, in Dutch)

An inner-ear organoid with vesicles, hair cells and nerve fibres▶ Watch in 3D

Extra: growing a mini-ear

± 2:45 · From a tube of blood to stem cells (hiPSC) and an inner-ear organoid with real hair cells. What you can measure in it, and how that differs from a minigene and from blood. With a day slider to grow it yourself.

What part 2 does not establish

That piece 23 (exon 23) is skipped is a prediction by five computational models (SpliceAI 0.89, Pangolin 0.79, SAI-10k, AlphaGenome, Carbon-3B), not yet a measurement. If it is indeed skipped, the rest follows arithmetically: piece 23 is 130 letters, and the first triplet of piece 24 that is read after it is TGA, a stop signal at position 763. That has been checked against the sequence itself (Ensembl GRCh38).

Whether the message is then cleared away or escapes has not been measured; the RNA analysis on my blood is under way. That a truncated protein of 762 building blocks cannot couple follows from the domain map (UniProt Q9UM54: the coupling regions lie between 835 and 1285); the coupling mode itself is inferred in UniProt from related proteins. Whether a free, truncated motor does harm in some other way is deliberately left open in this animation.

What the organoid animation does not establish

The steps follow the published protocols (Koehler et al. 2017; Nature Protocols 2026): four signalling pathways, hair cells around day 40, culture up to day 150. Which compound is added on which day has been left out. The standard organoid resembles a young balance organ, not an adult cochlea; cochlear versions are in development. The turnaround time of almost a year for a new patient line is an estimate. The comparison table (minigene, blood, organoid) summarises what each method can measure; it is not the outcome of an experiment. The measurements are phrased as what could be done: this explains the method, it does not announce a study.

What part 3 does not establish

What goes wrong without myosin VI (the outer membrane lifts off the floor, the hairs fuse from the base up) comes from mice that have no myosin VI at all (Snell's waltzer; Self et al. 1999, PMID 10525338). That is not my situation: I have one working copy.

That with half a dose it happens more slowly, because the base of the hairs wears down over years, is also a mouse finding (heterozygous Myo6 mice, PMID 34619316) and is therefore shown as "presumably". Whether my second copy is missing entirely or exists as a truncated version has not been measured yet; that analysis is under way.

The position per pitch in the try-it-yourself section follows the Greenwood function for the human ear. The boundary where the damage begins is sketched, not measured. The head is a stylised silhouette; in reality the cochlea is about 1 cm wide and has three channels, simplified here to a single tube with the basilar membrane inside.

What part 4 does not establish

This animation states that half a dose of MYO6 is enough to cause hearing loss. That rests on one study, in mice (PMID 34619316): heterozygous Myo6-null mice develop mild but progressive hearing loss. That is not human data.

What that does not resolve, as the video also says: why carriers of the recessive form hear normally with the same half dose. Three explanations are conceivable (a mouse is not a human; their hearing has rarely been measured carefully; their variant may not be a complete knockout) and none of them has been studied. So it is one mouse study against one human observation.

Furthermore, dominant-negative damage is not ruled out; only the argument that it would be needed has fallen away. The constraint figures (74 observed versus 179 expected loss-of-function variants) come from gnomAD v4 and are a population statistic, not a measurement on me. The escape fraction of my own variant has not been measured yet; that analysis is under way. That is why the animation says my father's copy "makes nothing, or a truncated version".

The green window in the dosage meter is sketched. Only three points are observations: no myosin VI (severe, congenital), half (in me and in the mice: hearing loss) and one and a half to almost two times too much (one family, Hilgert 2008). Where "enough" exactly begins and ends has not been measured.

Where things stand now

On 27 July blood was drawn, and that will decide which treatment can work later

Cells are being grown from that blood. They are used to measure what really happens to that faulty working copy. There are two possibilities, and the difference is not academic.

Does the cell clear away the broken copy completely?

Then the broken copy simply makes nothing, and I just have too little motor protein. A treatment could then add a working copy. That is the simplest route, and since April 2026 there has been an approved inner-ear gene therapy that works exactly like that (for a different gene).

Or does a little slip through after all?

Then there is a half motor in the cell that may get in the way. Adding a copy will not help enough, and the error itself has to be corrected. That is possible in principle too, but it is a different and heavier design.

And this is where it gets stuck. The first question (is it indeed cut wrongly) is answered by the hospital laboratory. The second question (how much slips through) falls outside what a diagnostic lab does: that is research. Three labs have been asked so far and all three kindly said no, each for a good reason. Finding the fourth lab is the real bottleneck right now.

What I am pursuing in parallel

Not waiting for a single route. Four tracks at once, with very different horizons and very different odds. I am honest about which one really matters.

Main track

Adding the gene, or changing the letter back

Either add a working copy with a viral vector, or change the wrong letter back in place. The first ever cochlear gene therapy was approved in April 2026, for a different hearing gene. For MYO6 there is preclinical work, but no candidate yet.

First MYO6 trial realistically 2028–2032

Watching

Making cells younger

Partial reprogramming, aimed at the deterioration that comes with age. The first human was treated on 9 June 2026, but in the eye, not the ear.

5–10 years to use in hearing

Speculative

Boosting DNA repair, borrowed from whales

A whale protein that improves the repair of DNA damage might limit damage in the cochlea. Only tested in animals so far.

Proof of concept in animals

Fallback

Bypassing the ear altogether

Direct stimulation of the cortex, bypassing the ear and the auditory nerve. Only relevant if the other three tracks yield nothing. There is no programme for hearing yet.

5–10+ years, experimental

There is an operation that would help me hear better right now. I am deliberately not having it.

That is a real trade-off, not a principle. The low-frequency hearing I still have is exactly the tissue a future gene therapy would target. Among people who received a cochlear implant like this, half had no usable residual hearing left after five and a half years. Giving it up may mean giving up the treatment that does not exist yet.

There are two developments that could tip that decision within a few years, and I follow both. What I have revised in the meantime: my aversion originally came from an online sound demo that sounded terrible. Those demos turn out to be a poor predictor of what an implant really sounds like (about 1.9 out of 10 for similarity, rated by people who can compare the two). The decision stands, but on different grounds.

Concretely

What you can do, even if you know nothing about this

Three things. Two of them have nothing to do with biology.

  1. 1
    Do you know someone with hereditary hearing loss in their family?
    For MYO6/DFNA22, one family in the Netherlands has been described in the literature, in 2013, and I am the second. That number is the problem. In Nijmegen a pattern emerged: the hearing genes with a real research programme are exactly the genes with their own patient foundation. MYO6 has none. Finding more families is the first step, and that happens through people, not labs.
  2. 2
    Do you know someone in gene therapy, RNA or hearing research?
    One introduction does more than ten emails to strangers. That has been proven by now: the emails that worked came through someone, or contained a very small, concrete request.
  3. 3
    Share this page.
    Every extra pair of eyes can open a door. That is not meant as a pleasantry; it is literally how the useful contacts so far have come about.

Want to read more?